Phoenix Asia Holdings Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Revenue Annually7.4M
Net Income Annually1M
Semi-Annual Revenue (H1 FY2026) Quarterly3.5M
Semi-Annual Net Income (H1 FY2026) Quarterly198.3K
Watch Items
- Closing of the ACEA Pharma AcquisitionTrigger: Regulatory and Nasdaq approvals, including Hart-Scott-Rodino antitrust clearanceAction: Monitor SEC filings (Form 6-K or 8-K) for confirmation of transaction closing and renaming of the entity to ACEA Pharma, Inc.
- Shareholder Dilution from 100 Million New SharesTrigger: Issuance of 100,000,000 ordinary shares to ACEA Therapeutics, Inc.Action: Evaluate the impact of the ~82% post-deal ownership by ACEA Therapeutics on minority shareholders and stock liquidity.
- Conversion of the $20 Million Promissory NoteTrigger: Conversion price of $10.00 per share by Phoenix Prosperity Investment LimitedAction: Track potential issuance of up to 2,000,000 additional ordinary shares upon conversion of the note.
Research as of 19 Jun 2026